Evidence map›Paper›PMID 39762698›Full record

ArticleBulletin of experimental biology and medicine2024

Complex of Angiotensin II with Modified Low-Density Lipoproteins: Behavioral and Hemodynamic Effects in Rats.

S M Tolpygo, B B Shoibonov, T S Zamolodchikova, A V Kotov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

S M TolpygoFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia. olpygo_sm@academpharm.ru.
B B ShoibonovFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
T S ZamolodchikovaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
A V KotovFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endogenous multiple modified LDL (mLDL) and the renin-angiotensin system play a significant role in the development of atherosclerosis. It has been found that by behavioral and hemodynamic parameters the physiological activity of angiotensin II (Ang II) in combination with mLDL is considerably modified due to weakening of its diuretic effect and the inversion of hypertensive and tachyarrhythmic effects. Atherosclerosis is a long-term pathological process, so a single administration of artificially synthesized Ang I-mLDL complexes can be considered a model of the first contact of the body with pathogenic factors. We believe that angiotensin complexes with mLDL participate in adaptive and compensatory mechanisms at the initial stages of atherosclerosis and later contribute to its progression.

Indexed as

Angiotensin IIAtherosclerosisLipoproteins, LDLAnimalsBlood PressureHemodynamicsHypertensionMaleRatsRats, WistarRenin-Angiotensin SystemAngiotensin IILipoproteins, LDLangiotensin IIatherosclerosis modelingdrinking behaviorhemodynamicsmodified low-density lipoproteins

Identifiers

PMID39762698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.